Latest News
News Functions
Additional Functions
17 April 2024
Lonza Group AG
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
3 April 2024
Lonza Group AG
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
2 April 2024
Lonza Group AG
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
20 March 2024
Lonza Group AG
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
26 January 2024
Lonza Group AG
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Lonza Group AG
Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin
6 November 2023
Lonza Group AG
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
17 October 2023
Lonza Group AG
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
13 October 2023
Lonza Group AG
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
21 September 2023
Lonza Group AG
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
18 September 2023
Lonza Group AG
Board Announcement
21 July 2023
Lonza Group AG
Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin
1 June 2023
Lonza Group AG
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
10 May 2023
Lonza Group AG
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
5 May 2023
Lonza Group AG
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
20 April 2023
Lonza Group AG
Lonza Increases Straight Bond by CHF 150 Million
31 March 2023
Lonza Group AG
Lonza Launches Share Buyback Program of up to CHF 2 Billion
29 March 2023
Lonza Group AG
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
27 March 2023
Lonza Group AG
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
16 February 2023
Lonza Group AG
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
8 February 2023
Lonza Group AG
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
25 January 2023
Lonza Group AG
Lonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin
1 November 2022
Lonza Group AG
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
12 September 2022
Lonza Group AG
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
6 September 2022
Lonza Group AG
Lonza and Touchlight collaborate on end-to-end mRNA offering
22 July 2022
Lonza Group AG
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
1 July 2022
Lonza Group AG
Maria Soler Nunez appointed as Head, Group Operations
Lonza Group AG
Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)
26 January 2022
Lonza Group AG
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza Group AG
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth